

MAY. 7. 2004 1:59PM AVENTIS US PAT DEPT
TO: US CENTRALIZED USPTO

NO. 2530 P. 1

FAX TRANSMITTAL
TO THE UNITED STATES PATENT OFFICE

Applicants Docket Number:
HMR2041US NP1


Applicants:
Kurt M. Kesseler

Serial No.
09/760,590

Filing Date:
January 16, 2001

Title of Invention:

Ethanol Solvate of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4R-(3S-hydroxy-1-methyl)piperidiny]·4H-1-benzopyran-4-one

CERTIFICATE OF TRANSMISSION	
I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, at (703) 872-9306, on	
Date of Deposit	May 7, 2004
Printed Name of Person Signing Certificate Bonnie Stein	
Signature 	

Total Number of Pages Sent: 19

Attorney: **Lawrence L. Martin**

Group Art Unit: 1625

Examiner: **Celia C. Chang**

TO: Mail Stop AF
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet, signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit account (18-1982) in the name of **Aventis Pharmaceuticals Inc.**

- | | |
|--|---|
| <input checked="" type="checkbox"/> Amendment Pursuant to 37 CFR <u>1.121(c)</u>
<u>and Response Pursuant to 37 C.F.R. 1.116</u>
- 11 pgs. | <input type="checkbox"/> Fee Transmittal |
| <input type="checkbox"/> Charge deposit account, in duplicate | <input type="checkbox"/> Petition under 37 CFR _____ |
| <input type="checkbox"/> Extension of Time Petition - 1 month - 1 pg. | <input checked="" type="checkbox"/> Other <u>FAX Transmittal for Certificate of Correction dated April 28, 2004 - 1 pg.</u>
<u>and Request for Certificate of Correction Under 35 U.S.C. 154/155 and 37 C.F.R. 1.322/323 faxed April 28, 2004 - 3 pgs.</u> |
| <input type="checkbox"/> Issue Fee Transmittal & Advance Order | <input checked="" type="checkbox"/> Other <u>Executed Declaration Under Rule 132 - 3 pgs.</u> |
| <input type="checkbox"/> Maintenance Fee Transmittal | <input type="checkbox"/> Other |

Receipt Confirmed:

Signed

Dated

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. www.aventis.com
NOTICE: The documents accompanying this telex/copy transmission are intended only for the use of the individual or entity named above. If you have received this telex/copy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)

MAY. 7. 2004 2:00PM AVENTIS US PAT DEPT

NO. 2530 P. 2

PATENT

Docket No.: HMR2041 US NP1
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Kurt M. Kesseler

Serial No.: 09/760,590

Filed: 01/16/01

Title: Ethanol Solvate of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4R-(3S-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-one

Examiner: Celia C. Chang

Art Unit: 1625

CERTIFICATE OF TRANSMISSION
I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, at (703) 872-9306, on

Date of Deposit: May 7, 2004

Printed Name of Person Signing Certificate: Bonnie Steiner

Signature: Bonnie Steiner

**AMENDMENT PURSUANT TO 37 C.F.R. § 1.121 (c) AND
RESPONSE PURSUANT TO 37 C.F.R. § 1.116**

Box AF

Commissioner for Patents

Washington, D.C. 20231

Sir:

This is in response to the outstanding Final Office Action dated February 11, 2004, Paper Number 20, for which a response is due by May 11, 2004, in the above-identified patent application. Applicants respectfully request entry of the following remarks and amendments. Applicants request reconsideration and withdrawal of all outstanding rejections in light of the aforesaid remarks and amendments.